Theravance Biopharma announced its YUPELRI inhalation solution — a once-daily, nebulized muscarinic antagonist for maintenance treatment of COPD — did not show a statistically significant difference from the dry powder inhaler Spiriva in adults with severe to very severe COPD and suboptimal peak inspiratory flow rate.
The phase 4 study was a randomized, double-blind, parallel-group study comparing improvements in lung function in adults with severe to very severe COPD following once-daily treatment over 12 weeks with either YUPELRI or Spiriva.
Despite the results, Theravance Biopharma CEO Rick Winningham said there were still some positives to take away from the study.
“While the primary endpoint in the phase 4 study was not met, YUPELRI demonstrated an efficacy and safety profile consistent with its performance in other clinical studies,” he said. “We look forward to sharing additional details from (the study) in the future, following additional data analyses.”
